EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Alphamab Oncology's Enterprise Value is HK$3,330.7 Mil.
Alphamab Oncology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-261.4 Mil. Therefore, Alphamab Oncology's EV-to-FCF for today is -12.74.
The historical rank and industry rank for Alphamab Oncology's EV-to-FCF or its related term are showing as below:
HKSE:09966'
s EV-to-FCF Range Over the Past 10 Years
Min: -30.59 Med: -12.33 Max: -6.17
Current: -12.4
During the past 7 years, the highest EV-to-FCF of Alphamab Oncology was -6.17. The lowest was -30.59. And the median was -12.33.
HKSE:09966's EV-to-FCF is ranked worse than 100% of 370
companies
in the Biotechnology industry
Industry Median: 8.835
vs HKSE:09966: -12.40
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Alphamab Oncology's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Alphamab Oncology's EV-to-FCF
For the Biotechnology subindustry, Alphamab Oncology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alphamab Oncology's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alphamab Oncology's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Alphamab Oncology's EV-to-FCF falls into.
Alphamab Oncology's current Enterprise Value is HK$3,330.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Alphamab Oncology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-261.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Alphamab Oncology's PE Ratio for today is calculated as:
Alphamab Oncology's share price for today is HK$2.63.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Alphamab Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.241.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Alphamab Oncology EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Alphamab Oncology's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Alphamab Oncology (HKSE:09966) Business Description
Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in discovery, development manufacturing and commercialization of biotherapeutics for cancer treatment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:09966 has been successfully added to your 